Your browser doesn't support javascript.
loading
Efficacy and safety of capecitabine-based first-line chemotherapy in advanced or metastatic breast cancer: a meta-analysis of randomised controlled trials.
Yin, Weijiao; Pei, Guangsheng; Liu, Gang; Huang, Li; Gao, Shegan; Feng, Xiaoshan.
Afiliação
  • Yin W; Department of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, PR, China.
  • Pei G; Department of Respiratory Medicine, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, PR, China.
  • Liu G; Department of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, PR, China.
  • Huang L; Department of Gynecology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, PR, China.
  • Gao S; Department of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, PR, China.
  • Feng X; Department of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, PR, China.
Oncotarget ; 6(36): 39365-72, 2015 Nov 17.
Article em En | MEDLINE | ID: mdl-26420815
We sought to evaluate the efficacy and safety of capecitabine-based therapy as first-line chemotherapy in advanced breast cancer. Randomised controlled trials of capecitabine monotherapy or combined treatment were included in the meta-analysis. PubMed, EMBASE, the Cochrane Library database and important meeting summaries were searched systematically. Outcomes were progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and grades 3-4 drug-related adverse events.Nine trials with 1798 patients were included. The results indicated a significant improvement with capecitabine-based chemotherapy compared with capecitabine-free chemotherapy in ORR (relative risk [RR] 1.14, 95% confidence interval [CI] 1.03 to 1.26, P = 0.013) and PFS (hazard ratio [HR] 0.77, 95% CI 0.69 to 0.87, P < 0.0001). Overall survival favoured capecitabine-based chemotherapy, but this was not significant. There were more incidences of neutropenia and neutropenic fever in the capecitabine-free chemotherapy group and more vomiting, diarrhoea and hand-foot syndrome in the capecitabine-based chemotherapy group. There were no significant differences in nausea, fatigue, cardiotoxicity or mucositis/stomatitis between the two treatment regimens.Capecitabine-based chemotherapy significantly improves ORR and PFS in patients with advanced breast cancer, but has no demonstrable impact on OS. Capecitabine-based regimens are suitable as first-line treatment for patients with advanced breast cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Capecitabina / Antimetabólitos Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Systematic_reviews Limite: Female / Humans Idioma: En Revista: Oncotarget Ano de publicação: 2015 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Capecitabina / Antimetabólitos Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Systematic_reviews Limite: Female / Humans Idioma: En Revista: Oncotarget Ano de publicação: 2015 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos